OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
March 05, 2020
The deal is expected to close during the first half of 2021.
February 28, 2020
The partners will explore Dyadic’s C1 gene expression platform in conjunction with IIBR’s express gene sequences and targets to develop a potential vaccine candidate and monoclonal antibodies.
February 27, 2020
The companies are entering into a development and manufacturing collaboration for the advancement and production of human monoclonal antibodies for the potential treatment of novel coronavirus.
February 26, 2020
The decision was made after it was determined that many of the event’s largest stakeholders would be unable to travel to the conference due to the novel coronavirus outbreak.
February 18, 2020
Sanofi will use a recombinant DNA platform that produces a genetic match to proteins found on the surface of COVID-19 to formulate the vaccine.
February 17, 2020
The agency is taking steps to monitor the supply chain and assist in the development of treatments.
February 14, 2020
The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.
February 13, 2020
The Native Antigen Company has commercially introduced antigens that have been specifically derived from the Wuhan strain of novel coronavirus, now named Covid-19.